Female Before and After Hormone Replacement Therapy: What Studies Measured Over Time

Ashley Harwyn, PA-C, ABAAHP  |  Published June 17, 2025  |  Last updated October 6, 2026  |  19 min read

The time points research uses for hot flashes, vaginal symptoms, side effects, and bone, and what happens when therapy stops.

This post does not show patient results, and it does not predict yours. It walks through what studies measured, at which time points, which side effects the guidance lists as common, and what the research says hormone therapy does not do, so you can compare your own notes with published numbers. If you are weighing treatment, our hormone therapy service page describes the order of the assessment: your history first, then testing chosen from that, then a plan with a review date attached.

• FDA's 2003 draft guidance asked estrogen trials to show a significant drop in hot flash frequency and severity within 4 weeks, maintained through 12 weeks.[3]
• In a Cochrane review of 24 placebo-controlled trials, oral hormone therapy reduced weekly hot flash frequency by 75% relative to placebo, and The Menopause Society says no other therapy has been found to provide more relief.[1][2]
• Lower doses may take 6 to 8 weeks to provide adequate symptom relief, according to The Menopause Society.[1]
• Improvement in vaginal and urinary symptoms of menopause typically occurs within a few weeks, but 12 weeks of treatment may be needed for maximum benefit.[4]
• Hormone therapy prevents bone loss while you take it, and bone density falls back to pretreatment levels within 1 to 2 years of stopping.[1]
• The 2022 statement found no observable difference in weight trajectory, does not recommend hormone therapy for cognitive decline, and says systemic therapy generally does not improve sexual interest apart from vaginal symptoms.[1]

What did studies measure first after starting HRT?

Hot flashes and night sweats, which the research calls vasomotor symptoms, are the symptoms with the most specific timing data in the sources cited here. When the FDA laid out in 2003 draft guidance how estrogen products should be tested for this use, it asked companies to show a clinically and statistically significant reduction in both frequency and severity within 4 weeks of starting treatment, maintained through 12 weeks.[3] That is not a promise for every woman, but it tells you the time frame the trials were built around: weeks, not months.

How big was the change in those trials? A Cochrane review pooled 24 double-blind, placebo-controlled trials with 3,329 women, lasting from three months to three years, and found that oral hormone therapy reduced weekly hot flash frequency by 75% relative to placebo, with severity significantly reduced as well.[2] The Menopause Society's 2022 position statement cites that same figure and adds that no other pharmacologic or alternative therapy has been found to provide more relief.[1] Considering the dose, oral and nonoral estrogen showed no appreciable difference in efficacy, and combined estrogen plus progestogen appears slightly more effective than estrogen alone.[1]

Dose matters for speed. Lower doses, such as oral estradiol of 0.5 mg or less or a 0.025 mg estradiol patch, may take 6 to 8 weeks to provide adequate symptom relief.[1] The 2022 statement sets the therapeutic goal as the most appropriate, often lowest, effective dose.[1] So on a lower dose, the time point the statement gives is 6 to 8 weeks, not the first few weeks.

Sleep is measured differently. The 2022 statement concludes that hormone therapy improves sleep in women with bothersome nighttime hot flashes by reducing nighttime awakenings, and that estrogen may have some effect on sleep independent of hot flashes.[1] In other words, the main sleep finding is about fewer nighttime awakenings in women whose night sweats wake them. If you want to know how long hot flashes tend to last without treatment, our guide on how long hot flashes last covers the natural course.

One caution about the first few weeks: symptoms can fluctuate on their own during menopause. In the Cochrane trials, women taking placebo also reported a 57.7% drop in hot flashes from the start of the study to the end.[2] The review says that is why therapies must be tested against placebo, and it is a reason not to judge from one good or bad week. A symptom diary, covered later, gives you more than one week to look at.

Weeks, months, a year: what time points do studies use?

Each symptom has its own time points in the research. The table below lines them up with the source for each one. Read it as what studies measured and what guidance says, not a schedule your body must keep or a result you should expect.

A few rows deserve a closer look. The vaginal and urinary changes of menopause are grouped under the name genitourinary syndrome of menopause (GSM), which includes dryness, burning, and irritation, urinary urgency and recurrent infections, and pain with sex.[4] The Menopause Society's 2020 statement notes that improvement typically starts within a few weeks but that 12 weeks of treatment may be needed for maximum benefit, and that symptoms will recur if treatment stops.[4] For bothersome GSM symptoms not relieved by over-the-counter products, in women who do not need systemic therapy, the 2022 statement recommends low-dose vaginal estrogen or other therapies.[1] Our post on whether vaginal estrogen is safe covers that choice in more depth.

The bone row is about prevention. In the Women's Health Initiative (WHI), which enrolled women aged 50 to 79, combined estrogen and progestin raised spine and hip bone density by 4.5% and 3.7% relative to placebo and reduced fracture risk.[1] That benefit persists only as long as therapy continues. Within a few months of stopping, markers of bone turnover returned to pretreatment values, and bone density fell to pretreatment levels within 1 to 2 years.[1] Hormone therapy is FDA approved to prevent bone loss, not to treat osteoporosis.[1]

Skin is the change many women hope to see in the mirror. The 2022 statement reports that estrogen therapy increased skin thickness, collagen and elastin content, and skin moisture, with fewer wrinkles.[1] Its summary is careful, though: estrogen “appears to have” beneficial effects on skin when given at menopause, a Level II rating rather than its strongest grade.[1] The sources cited here give no week-by-week skin timeline, so this post does not offer one.

Which side effects are common in the first few months?

The 2022 position statement lists the more common adverse events of hormone therapy: nausea, bloating, weight gain, fluid retention, mood swings (related to the progestogen), breakthrough bleeding, headaches, and breast tenderness.[1] Keep the weight gain entry next to a second finding from the same statement: women who used hormone therapy did not have observable differences in the trajectory of weight or body fat gain compared with women who did not, although the numbers are relatively small.[1]

How often did side effects make women quit in trials? In the Cochrane review, the occurrence of any adverse event was significantly higher on hormone therapy than on placebo.[2] But withdrawal because of adverse events, most commonly breast tenderness, swelling, joint pain, and psychological symptoms, was not significantly increased, even though those trials used fixed doses that could not be tailored to the individual woman.[2] MedlinePlus puts it simply: low doses of hormone therapy tend to have few side effects.[6]

Bleeding deserves its own note. If you still have a uterus, a progestogen is added to estrogen to protect the uterine lining, unless a specific estrogen combination product that does not need one is used.[1] Breakthrough bleeding is on the 2022 statement's list of more common adverse events, and the statement says unscheduled bleeding occurring more than 6 months after starting combined therapy should be investigated.[1] MedlinePlus advises contacting your provider if you have vaginal bleeding or other unusual symptoms during hormone therapy.[6]

Here is a practical way to sort what to do with early effects:

• Note it and raise it at your review: breast tenderness, bloating, headaches, or nausea, which the 2022 statement lists among the more common adverse events.[1]
• Contact your provider: vaginal bleeding or other unusual symptoms during hormone therapy.[6]
• Call 911 for chest pain, sudden shortness of breath, or sudden weakness, numbness, or trouble speaking. Seek same-day care for new swelling or pain in one leg. MedlinePlus notes that hormone therapy may increase the risk of blood clots.[6]

The 2022 statement also calls for shared decision-making on formulation, route, and dose, with adjustment tailored to symptom relief, side effects, and patient preferences.[1] That is the reason to bring side effects to a scheduled review rather than tough them out alone.

What the research says HRT does not change

This is the other half of an honest “before and after.” The 2022 statement is specific about what hormone therapy treats and what it is not recommended for, and knowing the difference can save a lot of disappointment.

Weight. The average weight gain during midlife and the menopause transition is 1.5 lb per year, and fat shifts toward a central pattern after menopause.[1] Women who used hormone therapy did not have observable differences in the trajectory of weight or body fat gain compared with women who did not, although the numbers are relatively small.[1] The statement adds that hormone therapy may help attenuate abdominal fat accumulation and weight gain in the transition, but the effect is small.[1] Our post on whether hormone therapy helps with weight loss goes further, and an InBody body composition scan estimates lean mass and fat mass and is better at showing change over time than as a single exact number.

Memory and brain fog. Hormone therapy is not recommended at any age to prevent or treat a decline in cognitive function or dementia.[1] Started after age 65, combined therapy in the WHI Memory Study doubled the risk of all-cause dementia.[1]

Mood. There is some evidence that estrogen has antidepressant effects in depressed perimenopausal women, but estrogen therapy is ineffective as a treatment for depressive disorders in postmenopausal women.[1] If low mood is a major part of your picture, it deserves its own evaluation; our mental health care page explains how we work alongside your therapist or psychiatrist.

Desire. Systemic hormone therapy generally does not improve sexual interest, arousal, or orgasm apart from its effect on vaginal symptoms.[1] Both systemic therapy and low-dose vaginal estrogen increase lubrication, blood flow, and sensation of vaginal tissues, which is real and worth having, but it is not the same as restoring desire.[1]

Bladder leaks. Systemic hormone therapy does not improve urinary incontinence and may increase stress incontinence, though low-dose vaginal estrogen may help with urgency, overactive bladder, and prevention of recurrent urinary tract infections.[1]

General quality of life in a large trial. The WHI randomly assigned 16,608 women aged 50 to 79 (mean age 63) to combined therapy or placebo. Combined therapy had no significant effects on general health, vitality, mental health, depressive symptoms, or sexual satisfaction, and at three years there were no significant benefits on any quality-of-life outcome.[5] The picture differs for women with symptoms to treat: in women with menopause symptoms, systemic therapy can improve menopause-specific quality of life.[1]